Status:
WITHDRAWN
Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent
Lead Sponsor:
Robert Fox
Collaborating Sponsors:
Case Western Reserve University
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
This study evaluates the safety of \[11C\]MeDAS, a PET radiotracer.
Detailed Description
Myelin PET imaging provides a new type of information regarding the integrity of the central nervous system based on molecular imaging of myelin. Preclinical studies have shown \[11C\] MeDAS uptake in...
Eligibility Criteria
Inclusion
- Subject reports no known physical diseases of the central nervous system including no history of mental health disorders.
- Capable of giving informed consent
- Efforts will be made to include approximately equal numbers of women and men. Efforts will be made to include individuals of diverse ethnicities, as reflected in the local clinic population.
Exclusion
- Age \<18 or \>65
- History of malignant hypertension or hypertensive crisis
- Known infectious disease requiring treatment during the course of the study
- Subject reported history of substance abuse
- inability to undergo an MRI or PET scan
Key Trial Info
Start Date :
July 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04333290
Start Date
July 24 2024
End Date
July 25 2024
Last Update
February 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195